Halberd Corporation (HALB)
USD 0.0
(-13.64%)
USD 0.0
(-13.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 74.84 Thousand USD | -83.31% |
| 2023 | 448.51 Thousand USD | -72.42% |
| 2022 | 1.62 Million USD | 89.87% |
| 2021 | 856.62 Thousand USD | -47.9% |
| 2020 | 1.64 Million USD | 7402.03% |
| 2019 | 21.91 Thousand USD | 54.05% |
| 2018 | 14.22 Thousand USD | -96.34% |
| 2017 | 388.78 Thousand USD | 333.29% |
| 2016 | 89.72 Thousand USD | 0.0% |
| 2008 | 44.08 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 10.85 Thousand USD | 23.23% |
| 2024 Q4 | 6885.00 USD | -36.57% |
| 2024 Q2 | 8809.00 USD | -81.6% |
| 2024 Q1 | 47.88 Thousand USD | 79.93% |
| 2023 Q3 | 80.26 Thousand USD | -24.98% |
| 2023 Q4 | 26.61 Thousand USD | -66.84% |
| 2023 Q1 | 233.63 Thousand USD | -10.33% |
| 2023 FY | 448.51 Thousand USD | -72.42% |
| 2023 Q2 | 106.98 Thousand USD | -54.21% |
| 2022 Q4 | 260.55 Thousand USD | -12.23% |
| 2022 Q3 | 296.85 Thousand USD | -58.43% |
| 2022 Q2 | 714.14 Thousand USD | 168.61% |
| 2022 FY | 1.62 Million USD | 89.87% |
| 2022 Q1 | 265.86 Thousand USD | 36.5% |
| 2021 Q4 | 194.77 Thousand USD | -14.31% |
| 2021 FY | 856.62 Thousand USD | -47.9% |
| 2021 Q3 | 227.31 Thousand USD | -96.01% |
| 2021 Q2 | 5.69 Million USD | -6.13% |
| 2021 Q1 | 6.06 Million USD | 0.0% |
| 2020 FY | 1.64 Million USD | 7402.03% |
| 2019 FY | 21.91 Thousand USD | 54.05% |
| 2018 FY | 14.22 Thousand USD | -96.34% |
| 2017 FY | 388.78 Thousand USD | 333.29% |
| 2016 FY | 89.72 Thousand USD | 0.0% |
| 2009 Q3 | 365.55 Thousand USD | 202.33% |
| 2009 Q2 | 120.91 Thousand USD | 712.7% |
| 2009 Q1 | 14.87 Thousand USD | 108.7% |
| 2008 Q3 | 157.66 Thousand USD | 174.37% |
| 2008 Q2 | 57.46 Thousand USD | 359062.5% |
| 2008 FY | 44.08 Thousand USD | 0.0% |
| 2008 Q1 | 16.00 USD | 0.0% |
| 2008 Q4 | -171.06 Thousand USD | -208.5% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.747% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 80.788% |
| Nascent Biotech, Inc. | 2.22 Million USD | 96.644% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 81.987% |
| Qrons Inc. | 643.67 Thousand USD | 88.373% |
| Rebus Holdings, Inc. | 664 Thousand USD | 88.729% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.448% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.799% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.87% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.533% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 98.516% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 94.396% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.914% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 98.478% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 71.404% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.913% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 97.434% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 95.017% |
| Mesoblast Limited | 5.9 Million USD | 98.732% |
| Marizyme, Inc. | 19.23 Million USD | 99.611% |
| Genus plc | 147.7 Million USD | 99.949% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.148% |
| Pharming Group N.V. | 225.49 Million USD | 99.967% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 96.347% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 94.421% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.103% |
| ContraFect Corporation | 56.88 Million USD | 99.868% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 98.302% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 94.939% |
| IMV Inc. | 37.7 Million USD | 99.802% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 97.318% |
| MultiCell Technologies, Inc. | 567.42 USD | -13089.877% |
| ONE Bio Corp. | 6.44 Million USD | 98.839% |
| Accustem Sciences Inc. | 3.74 Million USD | 98.002% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.913% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 85.931% |
| Q BioMed Inc. | 3.43 Million USD | 97.822% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.697% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 97.152% |
| Biomind Labs Inc. | 994.18 Thousand USD | 92.472% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.925% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 95.747% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 98.886% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 95.986% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 399.368% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 95.922% |
| GB Sciences, Inc. | 1.42 Million USD | 94.731% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.229% |
| HST Global, Inc. | 140.9 Thousand USD | 46.886% |
| CSL Limited | 3.44 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 93.347% |
| Enzolytics Inc. | 2.17 Million USD | 96.566% |
| Agentix Corp. | 1.37 Million USD | 94.544% |
| Resverlogix Corp. | 12.71 Million USD | 99.411% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 97.95% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.995% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 92.831% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 96.888% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 95.261% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 97.802% |
| AVAX Technologies, Inc. | 7.31 Million USD | 98.976% |
| Zenith Capital Corp. | 8.94 Million USD | 99.163% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.991% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -329.608% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 96.952% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 56.363% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 96.104% |
| Kadimastem Ltd | 2.41 Million USD | 96.895% |
| Helix BioMedix, Inc. | 1.97 Million USD | 96.205% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.311% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.674% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 58.761% |
| LadRx Corporation | 3.81 Million USD | 98.037% |
| Cell Source, Inc. | 4.32 Million USD | 98.27% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 91.896% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 91.896% |
| NovAccess Global Inc. | 2.46 Million USD | 96.966% |
| Affymax, Inc. | 39.38 Million USD | 99.81% |
| Itoco Inc. | 919.14 Thousand USD | 91.857% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 98.234% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 93.312% |
| Mobile Lads Corp. | 554.54 Thousand USD | 86.504% |
| CytoDyn Inc. | 18.05 Million USD | 99.586% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -197.358% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 65.993% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 94.729% |
| SYBLEU INC | 160.87 Thousand USD | 53.478% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 95.879% |
| International Stem Cell Corporation | 5.27 Million USD | 98.58% |
| Bioxytran, Inc. | 3.82 Million USD | 98.041% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -42.172% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -267.901% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.794% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 95.374% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 89.829% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 97.594% |
| Neutra Corp. | 243.82 Thousand USD | 69.305% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.571% |
| PureTech Health plc | 144.59 Million USD | 99.948% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.635% |
| IXICO plc | 4.7 Million USD | 98.41% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.149% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.936% |
| CSL Limited | 3.89 Billion USD | 99.998% |
| Cellectis S.A. | 97.32 Million USD | 99.923% |